10th Nov 2025 14:28
(Alliance News) - Cambridge Nutritional Sciences PLC on Monday said it expects full-year sales to be lower than the prior financial year, as it reported a 7% contraction in its top line during interim trading.
The London-based specialist medical diagnostics company focused on a personalised approach to health and nutrition reported a pretax loss of GBP397,000 in the six months to the end of September, widened from GBP196,000 a year earlier.
Revenue fell 6.6% to GBP3.9 million from GBP4.1 million, driven by order slowness in many of its key regions and with Chief Executive James Cooper stating "sales in the first half of this fiscal year have not reached our expectations".
Cambridge Nutritional noted the competitive nature of the European market, where it realised the biggest fall in sales, stating that it is "exploring all options" to ensure that it focuses sales coverage to the "most appropriate" regions.
Also hampering the bottom line were increased costs, as selling and marketing costs rose 36% to GBP839,000 from GBP617,000.
Cambridge Nutritional said it now expects full-year sales to fall below the prior year. In financial 2025, it reported GBP8.3 million in revenue.
The company tied this to longer-than-expected sales cycles for new customers. However, it noted that its sales pipeline continues to grow, with the business focused on driving new and existing sales in the second half.
Shares in the company were down 5.7% at 2.50 pence on Monday afternoon in London.
"The first half of this year has been frustrating. We have seen some regions showing good growth, particularly where we are closer to the end user, whilst other key areas have not achieved their budget," said Chair Carolyn Rand.
"We have therefore implemented a restructure of the sales teams to ensure more focus is given to understand the markets more deeply and deliver on customer needs and demands. This will take a little time to embed so we do not expect the second half to show any significant improvements...The positive news is that despite lower sales we have continued to grow our gross margin by another 2.3% in the first half and that profitability in the business continues at the adjusted earnings before interest, tax, depreciation and amortisation level, demonstrating the excellent work laying the foundations in these areas over the last few years.
The company reported interim adjusted Ebitda of GBP102,000, down from GBP227,000 a year prior.
By Christopher Ward, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Cambr Nutri Sci